Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866267 · ClinicalTrials.gov registry record · Phase 4
Switching Undetectables to Selzentry
A Phase 4 study of Human Immunodeficiency Virus and AIDS, sponsored by St. Hope Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01866267 is a Phase 4 study of Human Immunodeficiency Virus and AIDS that has completed, run by St. Hope Foundation. The registered enrollment target is 31 participants, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01866267, a Phase 4 study of Human Immunodeficiency Virus and AIDS, has completed, sponsored by St. Hope Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot single arm, single site, open-labeled switch study seeks to enroll thirty (30) HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] and switch them to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs.
Conditions Studied
Interventions
- DRUG Maraviroc
Study Locations (1)
Texas
- St. Hope Foundation, Inc. - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866267
The ClinicalTrials.gov registry entry for NCT01866267 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (83% lower). The listed sponsor is St. Hope Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Maraviroc is the first listed.
NCT01866267 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01866267 about?
NCT01866267 is a clinical study titled "Switching Undetectables to Selzentry". This pilot single arm, single site, open-labeled switch study seeks to enroll thirty (30) HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibito...
What is the current status of trial NCT01866267?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2013-01. Estimated completion is 2014-06.
What conditions does trial NCT01866267 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, AIDS.
What interventions are being tested in trial NCT01866267?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT01866267?
This trial is sponsored by St. Hope Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01866267 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
HIV Non-Occupational Post-Exposure Prophylaxis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.